New prospects in the management of functional reproductive disorders associated with polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with hyperandrogenism, anovulatory infertility and metabolic disorders. Along with hormonal therapy, reproductive disorders associated with polycystic ovary syndrome are managed with the help o...

Full description

Saved in:
Bibliographic Details
Published inMedicinskij sovet no. 9; pp. 34 - 38
Main Authors G. E. Chernukha, E. K. Kaprina, A. A. Naidukova
Format Journal Article
LanguageRussian
Published Remedium Group LLC 01.12.2015
Subjects
hyperinsulinemia
insulin resistance
metformin
myo-inositol
polycystic ovary syndrome (pcos)
therapy
гиперинсулинемия
инсулинорезистентность
метформин
синдром поликистозных яичников (спкя)
терапия
Online AccessGet full text

Cover

More Information
Summary:Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with hyperandrogenism, anovulatory infertility and metabolic disorders. Along with hormonal therapy, reproductive disorders associated with polycystic ovary syndrome are managed with the help of drugs which increase insulin sensitivity, reduce secretion of insulin and androgens. A literature review demonstrated that myo-inositol, one of nine stereoisomers of hexa-hydroxy alcohol inositol, also helps to regulate the menstrual cycle, restore ovulation and maturation of oocytes, as well as reduces insulin resistance and hyperandrogenism. Myo-inositol seems to be promising in the treatment of PCOS and significantly improves IVF results.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2015-9-34-38